Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
about
Sui generis: gene therapy and delivery systems for the treatment of glioblastomaTherapeutically engineered induced neural stem cells are tumour-homing and inhibit progression of glioblastoma.Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of surgically resected glioblastoma.Neural stem cell therapy for cancer.Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.Gliomagenesis and the use of neural stem cells in brain tumor treatmentA first-generation multi-functional cytokine for simultaneous optical tracking and tumor therapyAdvances in Viral Vector-Based TRAIL Gene Therapy for Cancer.Evaluating the effect of therapeutic stem cells on TRAIL resistant and sensitive medulloblastomasEffect of temozolomide on livin and caspase-3 in U251 glioma stem cells.Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway.Gene therapy for malignant glioma.TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivoFibrin matrices enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer.Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomasReal-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.Carbenoxolone enhances TRAIL-induced apoptosis through the upregulation of death receptor 5 and inhibition of gap junction intercellular communication in human glioma.Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.Strategies in gene therapy for glioblastoma.Applications of neural and mesenchymal stem cells in the treatment of gliomas.Viruses, gene therapy and stem cells for the treatment of human glioma.Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant gliomaPredicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide.Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma.Current evidence of temozolomide and bevacizumab in treatment of gliomas.Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors.Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.Lentiviral transfer of an inducible transgene expressing a soluble form of Gas1 causes glioma cell arrest, apoptosis and inhibits tumor growth.A novel molecule integrating therapeutic and diagnostic activities reveals multiple aspects of stem cell-based therapy.KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.Temozolomide sensitizes stem-like cells of glioma spheres to TRAIL-induced apoptosis via upregulation of casitas B-lineage lymphoma (c-Cbl) protein.Regulating the expression of therapeutic transgenes by controlled intake of dietary essential amino acids.Identification of Mitoxantrone as a TRAIL-sensitizing agent for Glioblastoma MultiformeTumor-homing cytotoxic human induced neural stem cells for cancer therapy.Intra-cavity stem cell therapy inhibits tumor progression in a novel murine model of medulloblastoma surgical resection
P2860
Q26850467-56DCC1B4-D465-4828-B094-BE4586C3898FQ27333831-1A8FAFC0-8901-42DB-866B-B3AF2F6B6A3DQ30843565-8BCD6183-8015-4C91-ACB3-44FDEC91AF63Q33704489-47CDE301-6F61-4F5E-8878-7B2467A33ED8Q33828114-F5A81FB9-C18D-463A-8B45-6C70B8B605A6Q34240433-2C3F347A-ECA1-4C60-A1C2-0B314EB34E81Q34310698-6D84E8B9-F407-4457-8F18-D7375E1D57A4Q34341900-823C2A8F-4C5A-40A0-9CB1-3E037CB4401FQ34384021-92F17194-E57A-4473-91C4-8876BCC1399EQ34474267-0534D85F-DE2F-42CD-B0BF-7CC68EC53F7EQ35048739-E047BDC8-19A4-4124-9DC2-94E77B9F71ADQ35419466-DB794EC9-251B-428F-B604-193E42C67A42Q35673628-021C7C6B-C8E4-4725-A3B0-989533C8C4EAQ36500367-6B13A244-F740-4F64-8323-2B220F4224EDQ36684365-9C39D8B1-6B1F-4CB6-952A-E6B675E55D6CQ36695971-1E56CA41-C1FC-4428-9915-7D6A6D3E8BE9Q36913828-3B2F77CC-BC30-464F-B3A1-83B842689535Q36936884-733B3528-D1D6-417B-A78A-A27DB64D9D55Q37049935-36DE0254-1246-477C-8055-3AFED49A1B23Q37403279-708584D0-2C1A-4043-A43D-B7FE37DB2197Q37420576-DBB1D2C1-A290-4BED-88BA-7444624CA9B8Q37483966-6FFB33B8-8AC7-4359-8B1D-F906110C3C26Q37567452-1A9A318B-AB61-470A-A2FD-24F1E96DFA8EQ37585453-F90F8058-8EEF-456C-839A-437D8A94DC89Q37641600-35E34000-435B-4013-A816-FBABFA8D90D8Q37818222-A5DC5C36-FCBA-4CF6-B554-EAAA108E9B8BQ38230650-6F90B8A0-8D3B-4432-BD7F-2E115AC8B8C7Q38730195-6A9559E3-A402-49DE-98A9-D85BF2DAC393Q38960128-02C680AB-2311-46EA-A565-1A3F400B5C66Q39649349-FB446B18-8EE9-477F-8C78-2C7701541282Q39744489-92D63FDB-6A49-4DC4-906C-B814BC0BF37DQ41084396-455DB851-453B-4D57-94E8-FA59FD5F404FQ42479312-ADE0AB9B-E10E-4B20-9F75-289932E5F7FAQ42494301-F2C19E5C-ED72-4D16-8C7A-5CCF9DA05CBAQ42577813-1038B19D-9D18-485F-AF5F-6DF211D7DE6FQ48329121-8028B539-3F6F-4C4E-A3E9-14CECBC2C9ECQ57640952-DBA23121-BFD1-43F4-A61A-2455B87CE771
P2860
Targeting multiple pathways in gliomas with stem cell and viral delivered S-TRAIL and Temozolomide
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Targeting multiple pathways in ...... vered S-TRAIL and Temozolomide
@en
Targeting multiple pathways in ...... ered S-TRAIL and Temozolomide.
@nl
type
label
Targeting multiple pathways in ...... vered S-TRAIL and Temozolomide
@en
Targeting multiple pathways in ...... ered S-TRAIL and Temozolomide.
@nl
prefLabel
Targeting multiple pathways in ...... vered S-TRAIL and Temozolomide
@en
Targeting multiple pathways in ...... ered S-TRAIL and Temozolomide.
@nl
P2093
P2860
P1476
Targeting multiple pathways in ...... vered S-TRAIL and Temozolomide
@en
P2093
Ernie Terwilliger
Khalid Shah
Marie Classon
Shawn Hingtgen
Xianghui Ren
P2860
P304
P356
10.1158/1535-7163.MCT-08-0640
P577
2008-11-01T00:00:00Z